Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Servings Per Container:Approx 24
Researchers recruited 338 adults who had a BMI over 30 or a BMI of 2730 with one or more weight-related conditions and were assigned to one of the following experimental groups or a placebo group: 1 mg of subcutaneous retatrutide 4 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg 4 mg of subcutaneous retatrutide, starting at an initial dose of 4 mg 8 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg 8 mg of subcutaneous retatrutide, starting at an initial dose of 4 mg 12 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg The trials promising results pave the way for further phase 3 research to evaluate retatrutides efficacy in comprehensive obesity management and its impact on associated health issues
Our expert team is with you every step of the way, offering science-backed support through secure virtual visits
Marchan, R., Hammond, C
This broader framing can make the value of treatment more visible to patients, but it also introduces variability in how success is defined
US$ 24.47
US$ 25.62
US$ 26.83
